← 返回

代谢综合征相关基因特征预测胰腺导管癌患者的预后。代谢失调与胰腺导管癌之间的新联系

英文原题:Metabolic syndrome related gene signature predicts the prognosis of patients with pancreatic ductal carcinoma. A novel link between metabolic dysregulation and pancreatic ductal carcinoma.

查看英文原题

Metabolic syndrome related gene signature predicts the prognosis of patients with pancreatic ductal carcinoma. A novel link between metabolic dysregulation and pancreatic ductal carcinoma.

PubMed 2021/12/20(内容时间) Cancer Cell Int Q1 · IF 7(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

研究概要

结果揭示了代谢基因在 PDAC 中的基本机制,并建立了一个可靠且可参考的特征来评估 PDAC 的预后。GMPS 被鉴定为 PDAC 中潜在的候选癌基因,可作为 PDAC 治疗的新型生物标志物和治疗靶点。

研究思路结论见上方概要

胰腺癌是全球最常见的恶性肿瘤之一。近年来,涉及肿瘤发展的特定代谢活动引起了广泛关注。在本研究中,我们希望探讨代谢与肿瘤进展之间的相关性。

本研究纳入了95例胰腺导管腺癌(PDAC)患者的回顾性分析,以及来自癌症基因组图谱(TCGA)、国际癌症基因组联盟(ICGC)和基因表达综合数据库(GEO)的PDAC患者。采用多因素Cox回归分析构建预后模型。通过加权基因共表达网络分析(WGCNA)探讨PDAC代谢与免疫之间的潜在联系。通过CIBERSORT评估高风险组与低风险组之间22种肿瘤浸润免疫细胞(TIICs)。此外,通过基因集富集分析(GSEA)探索高风险组与低风险组之间潜在的免疫相关信号通路。通过CCK-8、克隆形成和Transwell进一步研究关键基因GMPS在胰腺肿瘤发生中的作用。

采用Cox回归模型分析MetS因素的预后价值,并建立基于临床MetS的列线图。随后,我们基于TCGA数据库建立了一个代谢相关特征来预测PDAC患者的预后,并在ICGC数据库和GEO数据库中进行验证,以寻找MetS基因在PDAC中的独特分子机制。WGCNA结果显示,蓝色模块与风险评分相关,且发现蓝色模块中的基因富集于免疫相关信号通路。此外,CIBERSORT结果表明,T cells CD8、T cells Regulatory、Tregs NK cells Activated、Dendritic cells Activated和Mast cells Resting的比例在高风险组和低风险组之间存在差异。这些差异是PDAC患者不同预后的潜在原因。GSEA和蛋白质-蛋白质相互作用网络(PPI)进一步揭示,我们的代谢相关特征在免疫相关生物学过程中显著富集。此外,在PDAC细胞中敲低GMPS可抑制肿瘤细胞的增殖、迁移和侵袭,而过表达GMPS则表现相反。

展开英文摘要原文

Pancreatic cancer is one of the most common malignancies worldwide. In recent years, specific metabolic activities, which involves the development of tumor, caused wide public concern. In this study, we wish to explore the correlation between metabolism and progression of tumor.

A retrospective analysis including 95 patients with pancreatic ductal adenocarcinoma (PDAC) and PDAC patients from The Cancer Genome Atlas (TCGA), the International Cancer Genome Consortium (ICGC), and The Gene Expression Omnibus (GEO) database were involved in our study. Multivariate Cox regression analysis was used to construct the prognosis model. The potential connection between metabolism and immunity of PDAC was investigated through a weighted gene co-expression network analysis (WGCNA). 22 types of Tumor-infiltrating immune cells (TIICs) between high-risk and low-risk groups were estimated through CIBERSORT. Moreover, the potential immune-related signaling pathways between high-risk and low-risk groups were explored through the gene set enrichment analysis (GSEA). The role of key gene GMPS in developing pancreatic tumor was further investigated through CCK-8, colony-information, and Transwell.

The prognostic value of the MetS factors was analyzed using the Cox regression model, and a clinical MetS-based nomogram was established. Then, we established a metabolism-related signature to predict the prognosis of PDAC patients based on the TCGA databases and was validated in the ICGC database and the GEO database to find the distinct molecular mechanism of MetS genes in PDAC. The result of WGCNA showed that the blue module was associated with risk score, and genes in the blue module were found to be enriched in the immune-related signaling pathway. Furthermore, the result of CIBERSORT demonstrated that proportions of T cells CD8, T cells Regulatory, Tregs NK cells Activated, Dendritic cells Activated, and Mast cells Resting were different between high-risk and low-risk groups. These differences are potential causes of different prognoses of PDAC patients. GSEA and the protein-protein interaction network (PPI) further revealed that our metabolism-related signature was significantly enriched in immune-related biological processes. Moreover, knockdown of GMPS in PDAC cells suppressed proliferation, migration, and invasion of tumor cells, whereas overexpression of GMPS performed oppositely.

The results shine light on fundamental mechanisms of metabolic genes on PDAC and establish a reliable and referable signature to evaluate the prognosis of PDAC. GMPS was identified as a potential candidate oncogene with in PDAC, which can be a novel biomarker and therapeutic target for PDAC treatment.

论文信息

作者
Cai W、Bao W、Chen S、Yang Y、Li Y
第一作者单位
Department of Gastroenterology and Hepatology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.China
通讯作者单位
Department of Ultrasound, Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, 109 Xueyuanxi Road, Wenzhou, 325000, Zhejiang, People's Republic of China. liyy513@sjtu.edu.cn.China
期刊
Cancer cell international2021 Dec 20
原文标识
PubMed 34930261 · DOI 10.1186/s12935-021-02378-w